Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $24.4 million.

  • Fortress Biotech's Operating Expenses fell 3344.41% to $24.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.7 million, marking a year-over-year decrease of 998.14%. This contributed to the annual value of $168.1 million for FY2024, which is 2592.01% down from last year.
  • According to the latest figures from Q3 2025, Fortress Biotech's Operating Expenses is $24.4 million, which was down 3344.41% from $52.9 million recorded in Q2 2025.
  • Fortress Biotech's 5-year Operating Expenses high stood at $80.3 million for Q4 2021, and its period low was $24.4 million during Q3 2025.
  • In the last 5 years, Fortress Biotech's Operating Expenses had a median value of $52.9 million in 2025 and averaged $54.8 million.
  • In the last 5 years, Fortress Biotech's Operating Expenses surged by 11836.52% in 2021 and then tumbled by 4431.15% in 2023.
  • Over the past 5 years, Fortress Biotech's Operating Expenses (Quarter) stood at $80.3 million in 2021, then fell by 11.51% to $71.0 million in 2022, then tumbled by 44.31% to $39.6 million in 2023, then decreased by 1.53% to $39.0 million in 2024, then plummeted by 37.26% to $24.4 million in 2025.
  • Its Operating Expenses stands at $24.4 million for Q3 2025, versus $52.9 million for Q2 2025 and $35.5 million for Q1 2025.